US 11,866,468 B2
Methods for treatment of nephrotic syndrome and related conditions
Sumant S Chugh, Oak Park, IL (US)
Filed by Sumant S Chugh, Oak Park, IL (US)
Filed on Jul. 16, 2018, as Appl. No. 16/036,643.
Application 14/855,060 is a division of application No. 13/841,240, filed on Mar. 15, 2013, granted, now 9,139,629, issued on Sep. 22, 2015.
Application 16/036,643 is a continuation of application No. 14/855,060, filed on Sep. 15, 2015, granted, now 10,023,620.
Application 13/841,240 is a continuation in part of application No. 13/364,962, filed on Feb. 2, 2012, granted, now 9,475,850, issued on Oct. 25, 2016.
Application 13/364,962 is a continuation of application No. PCT/US2011/039255, filed on Jun. 6, 2011.
Claims priority of provisional application 61/438,854, filed on Feb. 2, 2011.
Claims priority of provisional application 61/351,866, filed on Jun. 5, 2010.
Prior Publication US 2020/0102357 A1, Apr. 2, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/16 (2006.01); C07K 1/00 (2006.01); C07K 14/00 (2006.01); C07K 17/00 (2006.01); C07K 16/00 (2006.01); C07K 14/47 (2006.01); A61K 38/12 (2006.01); C07K 14/765 (2006.01); A61K 38/42 (2006.01); A61K 35/16 (2015.01); A61K 38/04 (2006.01); C07K 14/76 (2006.01); A61K 38/38 (2006.01); A61K 38/00 (2006.01); C12N 15/00 (2006.01); C07K 14/515 (2006.01); C07K 14/775 (2006.01); A61K 9/127 (2006.01)
CPC C07K 14/47 (2013.01) [A61K 35/16 (2013.01); A61K 38/00 (2013.01); A61K 38/04 (2013.01); A61K 38/12 (2013.01); A61K 38/16 (2013.01); A61K 38/38 (2013.01); A61K 38/42 (2013.01); C07K 14/515 (2013.01); C07K 14/76 (2013.01); C07K 14/765 (2013.01); C12N 15/00 (2013.01); A61K 9/1275 (2013.01); C07K 14/775 (2013.01)] 15 Claims
 
1. A mutant angiopoietin-like protein 4 (Angptl4) polypeptide having decreased LPL inhibitory activity, increased resistance to cleavage, or a combination of the foregoing, wherein the mutant Angptl4 polypeptide has at least 95% sequence identity with SEQ ID NO: 9 or SEQ ID NO: 10 and wherein positions 39 and 40 of SEQ ID NO: 9 or SEQ ID NO: 10 are selected from the group consisting of: DK, DA, KE and AE, positions 76 and 80 of SEQ ID NO: 9 or SEQ ID NO: 10 are selected from the group consisting of: C, S, and A, and positions 161-164 of SEQ ID NO: 9 or SEQ ID NO: 10 are selected from the group consisting of: GAAG (SEQ ID NO: 29), AAVV (SEQ ID NO: 69), GVVA (SEQ ID NO: 49), SGGG (SEQ ID NO: 87), and VAVA (SEQ ID NO: 90).